These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling. Goepfert A; Lehmann S; Blank J; Kolbinger F; Rondeau JM Immunity; 2020 Mar; 52(3):499-512.e5. PubMed ID: 32187518 [TBL] [Abstract][Full Text] [Related]
23. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Blauvelt A; Chiricozzi A Clin Rev Allergy Immunol; 2018 Dec; 55(3):379-390. PubMed ID: 30109481 [TBL] [Abstract][Full Text] [Related]
24. Cytokines of the IL-17 family in psoriasis. Lauffer F; Eyerich K; Boehncke WH; Asadullah K; Beissert S; Ghoreschi K; Schön MP J Dtsch Dermatol Ges; 2020 Jul; 18(7):675-681. PubMed ID: 32447845 [TBL] [Abstract][Full Text] [Related]
25. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. Balato A; Scala E; Balato N; Caiazzo G; Di Caprio R; Monfrecola G; Raimondo A; Lembo S; Ayala F Expert Opin Biol Ther; 2017 Nov; 17(11):1363-1374. PubMed ID: 28791896 [TBL] [Abstract][Full Text] [Related]
26. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis. Kivelevitch DN; Menter A Immunotherapy; 2015; 7(4):323-33. PubMed ID: 25917624 [TBL] [Abstract][Full Text] [Related]
27. Conformational dynamics in interleukin 17A and 17F functional complexes is a key determinant of receptor A affinity and specificity. Waters LC; Veverka V; Strong SL; Muskett FW; Dedi N; Lawson ADG; Prosser CE; Taylor RJ; Henry AJ; Carr MD Cytokine; 2021 Jun; 142():155476. PubMed ID: 33706174 [TBL] [Abstract][Full Text] [Related]
29. Association between IL-17A, IL-17F and IL-17RA gene polymorphisms and susceptibility to psoriasis and psoriatic arthritis: a meta-analysis. Villalpando-Vargas FV; Rivera-Valdés JJ; Alvarado-Navarro A; Huerta-Olvera SG; Macías-Barragán J; Martínez-López E; Graciano-Machuca O Inflamm Res; 2021 Dec; 70(10-12):1201-1210. PubMed ID: 34705056 [TBL] [Abstract][Full Text] [Related]
30. Absence of interleukin-17 receptor a signaling prevents autoimmune inflammation of the joint and leads to a Th2-like phenotype in collagen-induced arthritis. Corneth OB; Mus AM; Asmawidjaja PS; Klein Wolterink RG; van Nimwegen M; Brem MD; Hofman Y; Hendriks RW; Lubberts E Arthritis Rheumatol; 2014 Feb; 66(2):340-9. PubMed ID: 24504806 [TBL] [Abstract][Full Text] [Related]
31. Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics. van den Berg WB; McInnes IB Semin Arthritis Rheum; 2013 Oct; 43(2):158-70. PubMed ID: 24157091 [TBL] [Abstract][Full Text] [Related]
32. An Overview of Interleukin-17A and Interleukin-17 Receptor A Structure, Interaction and Signaling. Krstic J; Obradovic H; Kukolj T; Mojsilovic S; Okic-Dordevic I; Bugarski D; Santibanez JF Protein Pept Lett; 2015; 22(7):570-8. PubMed ID: 25990083 [TBL] [Abstract][Full Text] [Related]
33. Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment. Prinz I; Sandrock I; Mrowietz U J Exp Med; 2020 Jan; 217(1):. PubMed ID: 31727784 [TBL] [Abstract][Full Text] [Related]
34. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy. Roman M; Chiu MW Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098 [TBL] [Abstract][Full Text] [Related]
35. The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties. Goepfert A; Lehmann S; Wirth E; Rondeau JM Sci Rep; 2017 Aug; 7(1):8906. PubMed ID: 28827714 [TBL] [Abstract][Full Text] [Related]
36. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis. Reis J; Vender R; Torres T BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372 [TBL] [Abstract][Full Text] [Related]